


Korea's CJ BIO introduces two new Bifidobacterium strains

09 July 2025 | News

Their introduction brings new scientific diversity and formulation potential to Southeast Asian partners seeking to meet the region's growing demand for premium gut health ingredients



Their introduction brings new scientific diversity and formulation potential to Southeast Asian partners seeking to meet the region's growing demand for premium gut health ingredients

South Korea's CJ BIO has introduced two new Bifidobacterium strains under its advanced BiomeNrich PRO G814 (Bifidobacterium bifidum) and PRO G952 (B. animalis subsp. lactis).

Unveiled at Vitafoods Europe 2025, these two human-origin strains reflect CJ BIO's strategy to provide diverse solutions for customers seeking innovative probiotic ingredients for gut health. Their introduction brings new scientific diversity and formulation potential to Southeast Asian partners seeking to meet the region's growing demand for premium gut health ingredients.

The inclusion of Bifidobacteria introduces new clinical potential, especially in targeting life-stage-specific microbiome challenges such as age-related declines in Bifidobacterium levels, which are associated with gastrointestinal discomfort.

BiomeNrich PRO G814 and PRO G952 are rooted in over 30 years of scientific research, supported by clinical trials and historical use. The safety of the products has been recognised by the U.S. FDA through GRAS (Generally Recognised as Safe) and NDIN (New Dietary Ingredient Notification), as well as being listed in the QPS (Qualified Presumption of Safety) in Europe. Additionally, their usability is supported by certifications, including Halal and Kosher status, catering to religious needs in the Southeast Asian market. These additional measures have been taken to ensure seamless integration into a wide range of finished products for dietary supplements and functional foods.